medigraphic.com
Centro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán

2021, Number 2

Next >>

Rev Biomed 2021; 32 (2)

Current global situation of chagas disease

Garg NJ

Language: English
References: 10
Page: 66-68
PDF size: 447.62 Kb.


Text Extraction

Trypanosoma cruzi has existed in humans for >9000 years. Parasite, vector and human disease were described by Carlos Chagas in 1909. Vectorial and congenital transmissions account for ~70% and 26% of new infections, respectively. The clinical course of Chagas Disease (CD) is generally presented with acute parasitemic phase, clinically asymptomatic indeterminate phase, and chronic phase when patients develop cardiac, colon, or neurological disorders. Heart failure is recognized as the major cause of death in CD patients. The global productivity gain by treating acute or chronic CD and preventing heart failure and death is estimated to be $8 billion US dollars in 2021- 2030. Thus, just the economic benefi ts make a strong case for new investments in controlling this disease.


REFERENCES

  1. Aufderheide AC, Salo W, Madden M, Streitz J, Buikstra J, Guhl F, et al. A 9,000-year record of Chagas' disease. Proc Natl Acad Sci U S A 2004, 101:2034-9. doi: 10.1073/pnas.0307312101.

  2. Chagas C: Nova tripanozomiase humana: estudos sob a morfologia e o ciclo evolutivo do Schizotrypanum cruzi n. gen., s. sp. Agente etiológico de nova entidade mórbida no homem. Mem Inst Oswaldo Cruz 1909, 1:159-218. doi.org/10.1590/S0074-02761909000200008.

  3. Lenk EJ, Redekop WK, Luyendijk M, Fitzpatrick C, Niessen L, Stolk WA, et al. Socioeconomic benefit to individuals of achieving 2020 targets for four neglected tropical diseases controlled/eliminated by innovative and intensified disease management: Human African trypanosomiasis, leprosy, visceral leishmaniasis, Chagas disease. PLoS Negl Trop Dis. 2018 Mar 13;12(3):e0006250. doi: 10.1371/journal.pntd.0006250.

  4. World Health Organization. Chagas disease: control and elimination. Report of the secretariat. WHO, Geneva, UNDP/World Bank/WHO, 2010, http://apps.who.int/gb/ ebwha/pdf_files/WHA63/A63_17-en.pdf.

  5. Basile L, Jansa JM, Carlier Y, Salamanca DD, Angheben A, Bartoloni, A et al. Working group on Chagas disease. Chagas disease in European countries: the challenge of a surveillance system. Euro Surveill. 2011;16(37):pii=19968. doi.org/10.2807/ ese.16.37.19968-en.

  6. Sanmartino M, Saavedra AA, Prat JG, Albajar-Vinas, P. Chagas and health promotion: dialogue inspired by Curitiba statement. Health Promotion International 2019, 34 (S1): i82-i91 doi.org/10.1093/heapro/day105.

  7. Coura JR, Viñas PA. Chagas disease: a new worldwide challenge. Nature 2010, 465(7301): S6-7. doi: 10.1038/ nature09221.

  8. Dias JC. Evolution of Chagas disease screening programs and control programs: historical perspective. Glob Heart. 2015, 10(3): 193-202. doi: 10.1016/j.gheart.2015.06.003.

  9. Rios L, Campos EE, Menon R, Zago MP, Garg NJ. Epidemiology and pathogenesis of maternal-fetal transmission of Trypanosoma cruzi and a case for vaccine development against congenital Chagas disease. Biochim Biophys Acta Mol Basis Dis. 2020,1866(3):165591. doi: 10.1016/j.bbadis.2019.165591.

  10. Rios LE, Vázquez-Chagoyán JC, Pacheco AO, Zago MP, Garg NJ. Immunity and vaccine development efforts against Trypanosoma cruzi. Acta Trop. 2019, 200:105168. doi: 10.1016/j.actatropica.2019.105168.




2020     |     www.medigraphic.com